Molecular determinants of resistance to antiandrogen therapy
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy. This increase in androgen receptor mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional ligand-binding domain. Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand, and by altering the normal response to antagonists. These findings provide insight toward the design of new antiandrogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“which is known to promote AI-type growth in human prostate cancer models (3)”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [35]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“Because xenograft-specific expression signatures are likely to obscure the gene expression changes responsible for the transition from hormone-sensitive to hormone-refractory state”
BackgroundShiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729 · cited 1×
“Because steroid receptor–antagonist complexes adopt a variety of conformation”
BackgroundThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“The postulated mechanisms to explain resistance to hormone therapy can be separated into three general categorie”
BackgroundThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · cited 1×
“The kinases and substrates responsible for androgen receptor activation in this setting are unknown, but it is presumed to occur through downstream phosphorylation of androgen receptor–associated proteins or through the androgen receptor itself, analogous to the estrogen recepto”
BackgroundLNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146 · cited 1×
“Previous work has shown that the agonist-versus-antagonist response of nuclear receptors, such as the estrogen receptor, is altered by increased expression of coactivators (such as SRC-1) or by decreased expression of corepressors (such as NCoR”
BackgroundNongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113
Cited by
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
“We performed hierarchical clustering using an AR-activated gene signature (28) on the training and validation TNBC tumor data sets.”
MethodIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
“Common Genomic Alterations in Androgen Receptor Signaling Pathway Members We also conducted a core pathway analysis of AR, which is essential for growth and differentiation of the normal prostate and is responsible for treatment failure in castration-resistant, metastatic disease (Chen et al., 2004; Tran et al., 2009).”
MethodSelf-citationEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
“Any cardiac adverse event 88 (10) 24 (3) 66 (8) 18 (2)”
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Self-citationDivergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
“(a) Potential models of tumor evolution toward the neuroendocrine phenotype include linear progression from primary untreated adenocarcinoma to CRPC-Adeno to CRPC-NE (1), independent progression of two distinct subclonal or clonal populations within the primary (2) or castration-resistant (4) CRPC-Adeno to either CRPC…”
BackgroundGarraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Self-citationMontgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
“Furthermore, Chen et al. have shown that increased AR expression is instrumental in the progression from androgen-dependent to castration-resistant growth in a xenograft model, with the degree of AR up-regulation observed sufficient to allow tumor cell proliferation in 80% lower androgen concentrations ( 3 ).”
BackgroundSelf-citationRebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M.-E., Efstathiou, E., Rathkopf, D., Shelkey, J., Yu, E. Y., Alumkal, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Self-citationMu, P., Zhang, Z., Benelli, M., Karthaus, W. R., Hoover, E., Chen, C.-C., Wongvipat, J., Ku, S.-Y., Gao, D., Cao, Z., et al. (2017) · Science · doi:10.1126/science.aah4307 · Cited by 1,050
Self-citationScher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Self-citationGlucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Arora, V. K., Schenkein, E., Murali, R., Subudhi, S. K., Wongvipat, J., Balbas, M. D., Shah, N., Cai, L., Efstathiou, E., Logothetis, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.012 · Cited by 986
“We previously examined the molecular basis of progression to CRPC in mouse models and discovered that increased AR expression was the primary mechanism (Chen et al., 2004).”
Self-citationAndrogen receptor: structure, role in prostate cancer and drug discovery
Tan, M. E., Li, J., Xu, H. E., Melcher, K., & Yong, E.-L. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.18 · Cited by 943
Rosenfeld, M. G., Lunyak, V. V., & Glass, C. K. (2006) · Genes & Development · doi:10.1101/gad.1424806 · Cited by 952
“While many specific models have been proposed (Feldman and Feldman 2001; Chen et al. 2004; Debes and Tindall 2004), one component may be related to inflammatory signals from macrophages based on direct cell–cell adhesion between macrophages and prostate cancer cell lines.”
BackgroundSelf-citationMolecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
“These findings have been most strongly supported by key experiments showing that xenografts that have been selected for castration resistance primarily differ from their parental androgen-dependent lines with respect to levels of AR expression (Chen et al. 2004).”
BackgroundAttard, G., Parker, C., Eeles, R. A., Schröder, F., Tomlins, S. A., Tannock, I., Drake, C. G., & de Bono, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(14)61947-4 · Cited by 905
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, K., Dhanireddy, S., Engelke, C., et al. (2014) · Nature · doi:10.1038/nature13229 · Cited by 927
“(2) Aligned reads were sorted using NovoSort and exact duplicates were removed using Samtools33.”
MethodIntegrative molecular concept modeling of prostate cancer progression
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, J. T., Rubin, M. A., Pienta, K. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1935 · Cited by 922
“Hormone-refractory metastatic cancers select for mechanisms to maintain androgen signaling (such as androgen receptor amplifications or mutation”
BackgroundAndrogen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902
“As AR is expressed in the vast majority of both ADPC and AIPC (Heinlein and Chang, 2004; Scher and Sawyers, 2005) and decreasing levels of AR protein expression reduces both ADPC and AIPC growth in model systems (Chen et al., 2004; Haag et al., 2005; Heinlein and Chang, 2004), it appears AR signaling pathways play a c…”
BackgroundGuo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
“metastatic PCAs in previous gene profiling studies (19, 37, 38).”
ResultHarris, W. P., Mostaghel, E. A., Nelson, P. S., & Montgomery, B. (2009) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1296 · Cited by 877
“Continued signaling through the AR has been postulated to occur via AR amplification, or via AR mutation that increases sensitivity to DHT and nonandrogenic steroid molecules or antiandrogens”
BackgroundKarantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 866
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
“Although the etiology of disease progression can be complex, it is thought that high AR expression resensitizes tumor cells to low levels of adrenal androgens (5).”
BackgroundDehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
“which may result from AR gene amplification and/or enhanced AR transcription, has been shown to sensitize the AR to castrate levels of androgens (24, 30).”
Self-citationSun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
Self-citationLocke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747
“We and others (14, 15, 29, 30) found that androgen-dependent genes become constitutively reexpressed in the absence of testicular androgens during CRPC progression and that down-regulation of AR expression following castration with small interfering RNA can suppress prostate cancer tumor growth (29, 30).”
BackgroundARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3948 · Cited by 662
“This cell-line was engineered to over-express AR (3–5 fold higher than parental LNCaP), thus mimicking the castration-resistant clinical state (2, 13).”
Self-citationAndrogen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
Shah, R. B., Mehra, R., Chinnaiyan, A. M., Shen, R., Ghosh, D., Zhou, M., MacVicar, G. R., Varambally, S., Harwood, J., Bismar, T. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2442 · Cited by 617
“Chen et al. ( 37 ) have recently demonstrated that the AR in androgen-independent prostate cancer can still be active and fueled by submicromolar amount of testosterone.”
BackgroundHieronymus, H., Lamb, J., Ross, K. N., Peng, X. P., Clement, C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S. M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.005 · Cited by 624
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
“We constructed the pCSUVCG (U6-shRNA-VHL-CMV-GFP) by ligating the Bam HI/ Eco RI digests of pCSCG and the U6-shRNA-VHL PCR produc”
MethodSelf-citationMostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S., Matsumoto, A. M., Nelson, P. S., & Montgomery, R. B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0728 · Cited by 588
“Importantly, a 2to 3-fold increase in expression of AR is known to render low androgen levels physiologically relevant in promoting AR driven growth (2), suggesting clinical treatment of Abi-R patients with more stringent ligand inhibition may be of benefit.”
Self-citationJoseph, J. D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., Maneval, E. C., Chen, I., Darimont, B., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0226 · Cited by 578
“Understanding the mechanisms of acquired resistance to 1 generation anti-androgens (10) was the first step towards the discovery and development of two 2 generation agents, enzalutamide and ARN-509 (8, 9).”
BackgroundKorpal, M., Korn, J. M., Gao, X., Rakiec, D. P., Ruddy, D. A., Doshi, S., Yuan, J., Kovats, S. G., Kim, S., Cooke, V. G., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0142 · Cited by 561
“A conserved feature of CRPC is the sustained activity of AR-signaling (6), by virtue of mechanisms including AR gene overexpression/amplification and AR gene mutations (3).”
BackgroundMechanisms of Androgen-Refractory Prostate Cancer
Debes, J. D., & Tindall, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048178 · Cited by 558
Identification of a Cell of Origin for Human Prostate Cancer
Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P., & Witte, O. N. (2010) · Science · doi:10.1126/science.1189992 · Cited by 554
Androgen receptor signaling in prostate cancer development and progression
Tindall, D., & Lonergan, P. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.83937 · Cited by 535
“A considerable body of evidence now exists that implicates extracellular peptide signals in the form of growth factors and cytokines in the maintenance of the transcriptional activity of AR in CRPC.”
BackgroundInfluentialAbida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., Danila, D., Rathkopf, D., Morris, M., Slovin, S., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00029 · Cited by 541
Self-citationMostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
“Intensive basic and clinical research efforts have identified several potential explanations that include increased sensitivity of the AR via gene amplification and/or overexpression (39, 40), alterations in coregulators that alter ligand sensitivity (41), AR mutations that broaden ligand specificity and confer sensit…”
BackgroundAnnala, M., Vandekerkhove, G., Khalaf, D., Taavitsainen, S., Beja, K., Warner, E. W., Sunderland, K., Kollmannsberger, C., Eigl, B. J., Finch, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0937 · Cited by 515
Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
Sansone, P., & Bromberg, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8907 · Cited by 515
“However, when castrationresistant disease develops, tumors often express higher levels of the AR, possibly through activated Stat3, which can transcriptionally regulate AR.(178-181) Thus, we may consider combining antiandrogens with antiStat3 drugs rather than with chemotherapy in hormone-refractory metastaticprostate…”
BackgroundAndersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J.-K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.027 · Cited by 503
Implementing Genome-Driven Oncology
Hyman, D. M., Taylor, B. S., & Baselga, J. (2017) · Cell · doi:10.1016/j.cell.2016.12.015 · Cited by 503
Hörnberg, E., Ylitalo, E. B., Crnalic, S., Antti, H., Stattin, P., Widmark, A., Bergh, A., & Wikström, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019059 · Cited by 498
“CRPC despite castrate levels of circulating testosterone [1,2] and”
BackgroundChandran, U. R., Ma, C., Dhir, R., Bisceglia, M., Lyons-Weiler, M., Liang, W., Michalopoulos, G., Becich, M., & Monzon, F. A. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-64 · Cited by 495
“to explain the ability of prostate cancer to recur in the presence of androgen ablation therapy [33,34].”
BackgroundTestosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B., & Mohler, J. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0525 · Cited by 488
Cai, C., He, H. H., Chen, S., Coleman, I., Wang, H., Fang, Z., Chen, S., Nelson, P. S., Liu, X. S., Brown, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.001 · Cited by 454
“Moreover, studies in xenograft models indicate that even modest increases in AR protein expression may alone render tumors resistant to castration and to available AR antagonists (Chen et al., 2004).”
BackgroundInfluentialPlasma AR and abiraterone-resistant prostate cancer
Romanel, A., Tandefelt, D. G., Conteduca, V., Jayaram, A., Casiraghi, N., Wetterskog, D., Salvi, S., Amadori, D., Zafeiriou, Z., Rescigno, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9511 · Cited by 441
“AR gain has been previously shown to be associated with increased AR expression in prostate cancers (24), which can drive resistance to androgen suppression in vitro (25, 26).”
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Davies, A. H., Beltran, H., & Zoubeidi, A. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.22 · Cited by 431
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
Pienta, K. J., & Bradley, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0067 · Cited by 430
Darshan, M. S., Loftus, M. S., Thadani-Mulero, M., Levy, B. P., Escuin, D., Zhou, X. K., Gjyrezi, A., Chanel-Vos, C., Shen, R., Tagawa, S. T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1417 · Cited by 432
“Continued AR signaling remains essential to PC progression following androgen withdrawal (castration), with recent data suggesting that intra-tumoral androgen synthesis stimulates PC growth in patients with castrate resistant prostate cancer (CRPC) [4].”
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 420
“In a comparison of paired primary and resistant xenografts, AR was the only gene consistently over-expressed in the resistant xenografts (Chen et al., 2004).”
BackgroundInfluentialAndrogen Signaling in Prostate Cancer
Dai, C., Heemers, H., & Sharifi, N. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030452 · Cited by 406
Sharma, N. L., Massie, C. E., Ramos-Montoya, A., Zecchini, V., Scott, H. E., Lamb, A. D., MacArthur, S., Stark, R., Warren, A. Y., Mills, I. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.010 · Cited by 405
Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397
“, 2001) and confers partial agonism on bicalutamide (Chen et al., 2004), suggest that bicalutamide is not a viable treatment option for patients who fail on enzalutamide due to AR F876L mutation.”
BackgroundSelf-citationPromotion of Bladder Cancer Development and Progression by Androgen Receptor Signals
Miyamoto, H., Yang, Z., Chen, Y.-T., Ishiguro, H., Uemura, H., Kubota, Y., Nagashima, Y., Chang, Y.-J., Hu, Y.-C., Tsai, M.-Y., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk113 · Cited by 401
JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer
Xiang, Y., Zhu, Z., Han, G., Ye, X., Xu, B., Peng, Z., Ma, Y., Yu, Y., Lin, H., Chen, A. P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700735104 · Cited by 395
Self-citationAndrogen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Sharp, A., Coleman, I., Yuan, W., Sprenger, C., Dolling, D., Rodrigues, D. N., Russo, J. W., Figueiredo, I., Bertan, C., Seed, G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122819 · Cited by 393
“Visceral (with/without bone) 1 (13) 1(4) 0.”
Targeting the androgen receptor pathway in prostate cancer
Chen, Y., Sawyers, C. L., & Scher, H. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.005 · Cited by 389
“death in both human and murine CRPC cell lines [11,12 ,13].”
Self-citationSahu, B., Laakso, M., Ovaska, K., Mirtti, T., Lundin, J., Rannikko, A., Sankila, A., Turunen, J., Lundin, M., Konsti, J., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.328 · Cited by 390
“AR amplification and overexpression are also major features of castration-resistant prostate cancers (Visakorpi et al, 1995; Chen et al, 2004), and retinoblastoma tumour suppressor controls prostate cancer progression through modulation of AR expression (Sharma et al, 2010).”
BackgroundMoilanen, A.-M., Riikonen, R., Oksala, R., Ravanti, L., Aho, E., Wohlfahrt, G., Nykänen, P. S., Törmäkangas, O. P., Palvimo, J. J., & Kallio, P. J. (2015) · Scientific Reports · doi:10.1038/srep12007 · Cited by 379
Interaction of Nuclear Receptors with the Wnt/β-Catenin/Tcf Signaling Axis: Wnt You Like to Know?
Mulholland, D. J., Dedhar, S., Coetzee, G. A., & Nelson, C. C. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0034 · Cited by 377
The biology of cancer testis antigens: Putative function, regulation and therapeutic potential
Fratta, E., Coral, S., Covre, A., Parisi, G., Colizzi, F., Danielli, R., Marie Nicolay, H. J., Sigalotti, L., & Maio, M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.02.001 · Cited by 375
Miki, J., Furusato, B., Li, H., Gu, Y., Takahashi, H., Egawa, S., Sesterhenn, I. A., McLeod, D. G., Srivastava, S., & Rhim, J. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4429 · Cited by 369
“Increased AR expression (49) or the aberrant AR signaling (the AR acts as an oncogene; ref.”
BackgroundYuan, X., Cai, C., Chen, S., Chen, S., Yu, Z., & Balk, S. P. (2014) · Oncogene · doi:10.1038/onc.2013.235 · Cited by 370
Viswanathan, S. R., Ha, G., Hoff, A. M., Wala, J. A., Carrot-Zhang, J., Whelan, C. W., Haradhvala, N. J., Freeman, S. S., Reed, S. C., Rhoades, J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.036 · Cited by 365
“Selective activation of the AR enhancer in mCRPC provides further evidence that a stepwise amplification of AR signaling is key in the transition to castration-resistance (Chen et al., 2004; Visakorpi et al., 1995).”
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364
“10.1016/j.ccr.2006.08.021 309 of resistance to antiandrogen therapy (Chen et al., 2004).”
InfluentialArmstrong, A. J., Halabi, S., Luo, J., Nanus, D. M., Giannakakou, P., Szmulewitz, R. Z., Danila, D. C., Healy, P., Anand, M., Rothwell, C. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01731 · Cited by 362
Prostate Cancer Stem Cells: A New Target for Therapy
Maitland, N. J., & Collins, A. T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1472 · Cited by 350
Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344
Self-citationTanaka, H., Kono, E., Tran, C. P., Miyazaki, H., Yamashiro, J., Shimomura, T., Fazli, L., Wada, R., Huang, J., Vessella, R. L., et al. (2010) · Nature Medicine · doi:10.1038/nm.2236 · Cited by 339
Self-citationJAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence
Santagata, S., Demichelis, F., Riva, A., Varambally, S., Hofer, M. D., Kutok, J. L., Kim, R., Tang, J., Montie, J. E., Chinnaiyan, A. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2500 · Cited by 338
“(2) suggests that increases in androgen receptor mRNA and protein are both necessary and sufficient to convert prostate cancer cells to a hormone-refractory state.”
BackgroundAR, the cell cycle, and prostate cancer
Balk, S. P., & Knudsen, K. E. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06001 · Cited by 333
“Indeed, it is now well established that such “androgen independent” prostate cancer remains exquisitely dependent on AR function [Chen et al., 2004; Cheng et al., 2006;Yuan et al., 2006].”
Drug resistance in metastatic castration-resistant prostate cancer
Seruga, B., Ocana, A., & Tannock, I. F. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.136 · Cited by 336
“During progression of CRPC, signaling from the AR is maintained by increased expression of AR, amplification of the AR gene and/or structural changes in the AR triggered by mutations”
BackgroundPositron emission tomography for prostate, bladder, and renal cancer
Schöder, H., & Larson, S. M. (2004) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2004.06.004 · Cited by 337
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 316
Sharma, A., Yeow, W.-S., Ertel, A., Coleman, I., Clegg, N., Thangavel, C., Morrissey, C., Zhang, X., Comstock, C. E. S., Witkiewicz, A. K., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci44239 · Cited by 331
“This is of significance, as forced AR deregulation alone is sufficient to induce CRPC transition in tumor models (23), and high AR levels are strongly correlated with increased risk of death from PCa (24).”
BackgroundChen, Y., Clegg, N. J., & Scher, H. I. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70229-3 · Cited by 324
“These observations along with recent results from cellular and mouse model systems suggest reclassification as partial agonists (10,26).”
Rocchi, P., So, A., Kojima, S., Signaevsky, M., Beraldi, E., Fazli, L., Hurtado-coll, A., Yamanaka, K., & Gleave, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3998 · Cited by 316
Takeda, D. Y., Spisák, S., Seo, J.-H., Bell, C., O’Connor, E., Korthauer, K., Ribli, D., Csabai, I., Solymosi, N., Szállási, Z., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.037 · Cited by 317
“These results phenocopywhat is observed in LNCaP cells overexpressing the AR gene, an established model for CRPC (Chen et al., 2004).”
InfluentialZhu, P., Zhou, W., Wang, J., Puc, J., Ohgi, K. A., Erdjument-Bromage, H., Tempst, P., Glass, C. K., & Rosenfeld, M. G. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.07.024 · Cited by 321
“Because androgen/ AR signaling exerts key roles in prostate cancer (Chen et al., 2004; Heinlein and Chang, 2004; Zhu et al., 2006), regulation of AR-dependent transcription by 2A-DUB implies that uH2A could be a disease-related mark, analogous to acetylation and methylation marks found to be”
BackgroundSelf-citationMechanisms of the androgen receptor splicing in prostate cancer cells
Liu, L. L., Xie, N., Sun, S., Plymate, S., Mostaghel, E., & Dong, X. (2014) · Oncogene · doi:10.1038/onc.2013.284 · Cited by 315
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
Bitting, R. L., & Armstrong, A. J. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-12-0394 · Cited by 311
“These variable results may be due to incomplete suppression of the PI3K/Akt/mTOR pathway with everolimus or due to inadequate activity of bicalutamide in patients with CRPC who have amplification of AR in their tumors (Chen et al. 2004).”
BackgroundRice, M. A., Malhotra, S. V., & Stoyanova, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00801 · Cited by 309
“This agonist switching results in increased AR mRNA and protein levels, leading to resistance to antiandrogen therapy (14).”
BackgroundAn androgen receptor N-terminal domain antagonist for treating prostate cancer
Myung, J.-K., Banuelos, C. A., Fernandez, J. G., Mawji, N. R., Wang, J., Tien, A. H., Yang, Y. C., Tavakoli, I., Haile, S., Watt, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66398 · Cited by 305
“In spite of castrate levels of androgen, development of CRPC is considered to be causally related to continued transactivation of AR by mechanisms that may include amplification or overexpression of AR (3, 4), gain-of-function mutations that allow AR to be activated by steroids or antiandrogens (5, 6), ligand-independ…”
Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
Knudsen, K. E., & Scher, H. I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2660 · Cited by 307
JMJD3 is a histone H3K27 demethylase
Xiang, Y., Zhu, Z., Han, G., Lin, H., Xu, L., & Chen, C. D. (2007) · Cell Research · doi:10.1038/cr.2007.83 · Cited by 301
Self-citationNguyen, H. M., Vessella, R. L., Morrissey, C., Brown, L. G., Coleman, I. M., Higano, C. S., Mostaghel, E. A., Zhang, X., True, L. D., Lam, H.-M., et al. (2017) · The Prostate · doi:10.1002/pros.23313 · Cited by 300
“We observed a wide-range of responses to The Prostate these modalities, as also occurs in men with PC. Notably, results of studies using LuCaP PDXs identified AR amplification/activity as an important mechanism of resistance to ADT [45], supporting the use of enzalutamide (now FDA-approved for men with mCRPC) [45,46],…”
BackgroundInfluentialSelf-citationPartners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
Knudsen, K. E., & Penning, T. M. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.01.002 · Cited by 293
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
Asim, M., Tarish, F., Zecchini, H. I., Sanjiv, K., Gelali, E., Massie, C. E., Baridi, A., Warren, A. Y., Zhao, W., Ogris, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00393-y · Cited by 281
“Hence, we argue that ADT and PARP inhibitor combination treatment may be particularly beneficial in newly diagnosed high-risk PCa as (1) they have not generated castration resistance by means other than loss of HR and (2) the synthetic lethality is confined to the prostate and is likely to be well tolerated.”
BackgroundTargeting the p300/CBP Axis in Lethal Prostate Cancer
Welti, J., Sharp, A., Brooks, N., Yuan, W., McNair, C., Chand, S. N., Pal, A., Figueiredo, I., Riisnaes, R., Gurel, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0751 · Cited by 275
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
Drake, C. G., Doody, A. D. H., Mihalyo, M. A., Huang, C.-T., Kelleher, E., Ravi, S., Hipkiss, E. L., Flies, D. B., Kennedy, E. P., Long, M., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.027 · Cited by 289
“Expression of these androgen-regulated genes in castrate patients and TRAMP mice is most likely due in part to alterations in either the expression or activity of the androgen receptor, allowing activation in the absence of normal androgen levels (Taplin and Balk, 2004; Chen et al., 2004; Edwards et al., 2003; Hakimi…”
Schrader, A. J., Boegemann, M., Ohlmann, C.-H., Schnoeller, T. J., Krabbe, L.-M., Hajili, T., Jentzmik, F., Stoeckle, M., Schrader, M., Herrmann, E., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.06.042 · Cited by 284
“It is known from previous studies that AR mutations in the LBD can convert steroidal and nonsteroidal antiandrogens such as cyproterone acetate, hydroxyflutamide, or bicalutamide from an antagonist to an agonist [24–27].”
Shore, N. D., Chowdhury, S., Villers, A., Klotz, L., Siemens, D. R., Phung, D., van Os, S., Hasabou, N., Wang, F., Bhattacharya, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00518-5 · Cited by 278
Logothetis, C. J., Basch, E., Molina, A., Fizazi, K., North, S. A., Chi, K. N., Jones, R. J., Goodman, O. B., Mainwaring, P. N., Sternberg, C. N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70473-4 · Cited by 280
Mahajan, N. P., Liu, Y., Majumder, S., Warren, M. R., Parker, C. E., Mohler, J. L., Earp, H. S., & Whang, Y. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700420104 · Cited by 274
Androgen‐responsive long noncoding RNA CTBP1‐AS promotes prostate cancer
Takayama, K., Horie‐Inoue, K., Katayama, S., Suzuki, T., Tsutsumi, S., Ikeda, K., Urano, T., Fujimura, T., Takagi, K., Takahashi, S., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.99 · Cited by 278
“In addition, p21, which is a target of p53 and SMAD3 and is downregulated in AR-dependent CRPC (Wang et al , 2001), was also repressed by 48-h androgen treatment in a CTBP1-AS -dependent manner (Figure 7G and Supplementary Figure S21B).”
Influential
Metadata
- Authors
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Howard Hughes Medical Institute (US)
- University of Washington (US)
- Corresponding author
- Sawyers, Charles L
- Venue
- Nature Medicine
- Published
- 2003-12-21
- Volume
- 10
- Issue
- 1
- Pages
- 33-39
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2003955264
- Cited by
- 2,278
- References
- 50
- Citations by year
- 2026: 21 · 2025: 40 · 2024: 40 · 2023: 72 · 2022: 59 · 2021: 86 · 2020: 68 · 2019: 82 · 2018: 99 · 2017: 110 · 2016: 106 · 2015: 119 · 2014: 128 · 2013: 156 · 2012: 155
- FWCI
- 69.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- prostate cancer, antiandrogen resistance, androgen receptor, castration-resistant prostate cancer, androgen receptor ligand-binding domain, coactivator recruitment, corepressor recruitment, androgen receptor target genes
- MeSH terms
- Androgen Antagonists, Base Sequence, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, DNA Primers, Disease Progression, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.